Ngā hua rapu - Heidrun Bosch‐Traberg

  • E whakaatu ana i te 1 - 6 hua o te 6
Whakamahine hua
  1. 1
    Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36‐week, randomized, double‐blind, parallel‐group trial

    Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36‐week, randomized, double‐blind, parallel‐group trial mā Yutaka Seino, Shizuka Kaneko, Shuichi Fukuda, Takeshi Osonoi, Toshihiko Shiraiwa, Keiji Nishijima, Heidrun Bosch‐Traberg, Kohei Kaku

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial

    Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial mā Katherine R. Tuttle, Stephen C. Bain, Heidrun Bosch‐Traberg, Kamlesh Khunti, Søren Rasmussen, Ekaterina Sokareva, David Z. Cherney

    I whakaputaina 2024
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo

    Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney fun... mā Katherine R. Tuttle, Heidrun Bosch‐Traberg, David Z.I. Cherney, Samy Hadjadj, Jack Lawson, Ofri Mosenzon, Søren Rasmussen, Stephen C. Bain

    I whakaputaina 2023
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial

    Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Cl... mā Melanie J. Davies, Stephen C. Bain, Stephen L. Atkin, Peter Rossing, David A. Scott, Минара Шамхаловна Шамхалова, Heidrun Bosch‐Traberg, Annika Syrén, Guillermo E. Umpierrez

    I whakaputaina 2015
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

    The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease mā Peter Rossing, Florian M.M. Baeres, George L. Bakris, Heidrun Bosch‐Traberg, Mette Gislum, Stephen Gough, Thomas Idorn, Jack Lawson, Kenneth W. Mahaffey, Johannes F.E. Mann, Henriette Mersebach, Vlado Perkovic, Katherine R. Tuttle, Richard Pratley

    I whakaputaina 2023
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

    Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial mā Johannes F.E. Mann, Peter Rossing, George L. Bakris, Nicolas Belmar, Heidrun Bosch‐Traberg, Robert S. Busch, David M. Charytan, Samy Hadjadj, Pieter Gillard, José Luis Górriz, Thomas Idorn, Linong Ji, Kenneth W. Mahaffey, Vlado Perkovic, Søren Rasmussen, Roland E. Schmieder, Richard E. Pratley, Katherine R. Tuttle

    I whakaputaina 2024
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: